Candidemia surveillance in Iowa: Emergence of echinocandin resistance

Diagnostic Microbiology and Infectious Disease

Volumn 79, Issue 2, 2014, Pages 205-208

  Matsumoto, Eiyu ^a   Boyken, Linda ^a   Tendolkar, Shailesh ^a   Mcdanel, Jennifer ^a   Castanheira, Mariana ^b   Pfaller, Michael ^a,b   Diekema, Daniel ^a  

^a UNIVERSITY OF IOWA   (United States)

^b JMI LABORATORIES   (United States)

Author keywords

Antifungal resistance; Bloodstream infection; Candida; Echinocandin; Surveillance

Indexed keywords

AMPHOTERICIN; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT; FUNGAL PROTEIN;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BLOODSTREAM INFECTION; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDEMIA; FEMALE; FKS1 GENE; FKS2 GENE; FUNGAL GENE; FUNGAL VIRULENCE; FUNGUS IDENTIFICATION; FUNGUS ISOLATION; GENE MUTATION; HUMAN; MALE; NONHUMAN; PRIORITY JOURNAL; SPECIES DISTRIBUTION; ADOLESCENT; ADULT; AGED; CANDIDA; CHILD; CLASSIFICATION; DRUG EFFECTS; EPIDEMIOLOGICAL MONITORING; EPIDEMIOLOGY; GENETICS; INFANT; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; MUTATION; NEWBORN; PRESCHOOL CHILD; PREVALENCE; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CANDIDA; CANDIDEMIA; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; EPIDEMIOLOGICAL MONITORING; FEMALE; FLUCONAZOLE; FUNGAL PROTEINS; HUMANS; INFANT; INFANT, NEWBORN; IOWA; MALE; MIDDLE AGED; MUTATION; PREVALENCE; YOUNG ADULT;

EID: 84900476258     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2014.02.016     Document Type: Article

References (22)

1. Alexander B.D., Johnson M.D., Pfeiffer C.D., et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 2013, 56:1724-1732.
2. Arendrup M.C., Perlin D.S., Jensen R.H., et al. Differential in vivo activity of anidulafungin, caspofungin, and micafungin against C. glabrata with and without FKS mutations. Antimicrob Agents Chemother 2012, 56:2435-2442.
3. Berrouane Y.F., Herwaldt L.A., Pfaller M.A. Trends in antifungal use and epidemiology of nosocomial yeast infections in a university hospital. J Clin Microbiol 1999, 37:531-537.
4. Castanheira M., Woosley L.N., Diekema D.J., Messer S.A., Jones R.N., Pfaller M.A. Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains. Antimicrob Agents Chemother 2010, 54:2655-2659.
5. Castanheira M., Woosley L.N., Messer S.A., Diekema D.J., Jones R.N., Pfaller M.A. Frequency of fks mutations among Candida glabrata isolates from a 10-year global collection of bloodstream infection isolates. Antimicrob Agents Chemother 2014, 58:577-580.
6. Cleveland A.A., Farley M.M., Harrison L.H., Stein B., Hollick R., Lockhart S.R., Magill S.S., Derado G., Park B.J., Chiller T.M. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. Clin Infect. Dis 2012, 55:1352-1361.
7. Clinical and Laboratory Standards Institute (CLSI) Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard-third edition CLSI M27-A3 2007, CLSI, Wayne, PA.
8. Diekema D.J., Messer S.A., Brueggemann A.B., Coffman S.L., Doern G.V., Herwaldt L.A., Pfaller M.A. Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol 2002, 40:1298-1302.
9. Espinel-Ingroff A., Pfaller M.A., Bustamante B., et al. A multi-laboratory study of epidemiological cutoff values for azole-resistance detection of eight Candida spp. to fluconazole, posaconazole and voriconazole. Antimicrob Agents Chemother 2014, (in press).
10. Forrest G.N., Weekes E., Johnson J.K. Increasing incidence of Candida parapsilosis candidemia with caspofungin use. J Infect 2008, 56:126-129.
11. Garcia Effron G., Katiyar S.K., Park S., Edlind T.D., Perlin D.S. A naturally occurring proline-to-alanine amino acid change in FKS1p in Candida parapsilosis, Candida orthopsilosis and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob Agents Chemother 2008, 52:2305-2312.
12. Hidron A., Edwards J.R., et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Cont Hosp Epidemiol 2008, 29:996-1011.
13. Ostrosky-Zeichner L. Candida glabrata and FKS mutations: witnessing the emergence of the true multidrug-resistant Candida. Clin Infect Dis 2013, 56:1733-1734.
14. Pappas P.G., Rex J.H., Lee J., et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003, 37:634-643.
15. Pfaller M.A., Diekema D.J. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007, 20:133-163.
16. Pfaller M.A., Messer S.A., Hollis R.J., et al. Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007. J Clin Microbiol. 2009, 47:3185-3190.
17. Pfaller M.A., Andes D., Diekema D.J., et al. Wild-type distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updates 2010, 13:180-195.
18. Pfaller M.A., Diekema D.J., Andes D., et al. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updates 2011, 14:164-176.
19. Pfaller M.A., Castanheira M., Lockhart S., et al. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistance bloodstream isolates of Candida glabrata. J Clin Microbiol 2012, 50:1199-1203.
20. Pfeiffer C.D., Garcia-Effron G., Zaas A.K., et al. Breakthrough invasive candidiasis in patients on micafungin. J Clin Microbiol 2010, 48:2373-2380.
21. Sterling T.R., Gasser R.A., Ziegler A. Emergence of resistance to amphotericin B during therapy for Candida glabrata infection in an immunocompetent host. Clin Infect Dis 1996, 23:187-188.
22. Trick W.E., Fridkin S.K., Edwards J.R., Hajjeh R.A., Gaynes R.P. Secular trend of hospital acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002, 35:627-630.